News overview

Sliertjes1
News
4 May 2022
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Joop kroes
News
3 May 2022
In memoriam: Joop Kroes
We received the sad news that Joop Kroes passed away last month. Joop was one of the first patient representatives of Oncode’s Clinical Advisory Board (CAB). He has always been full of enthusiasm for the CAB and Oncode’s Clinical Proof of Concept Programme.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
1
News
29 April 2022
Missing enzyme identified: how MATCAP works and affects brain development
Oncode Investigator Thijn Brummelkamp’s lab (NKI) previously identified Vasohibins as detyrosinating enzymes, but most cells contain detyrosinated microtubules even when the two Vasohibin genes are deleted. The team now identified MATCAP as a new enzyme involved in this process. Together with Oncode Investigator Anastassis Perrakis’ lab (NKI) they then showed how MATCAP works and how it engages with microtubules.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Diary of a Lonely Cell
News
28 April 2022
Looking at science with new eyes
Oncode Science Art prize winning stories and everything on how to enter your best microscopy images and videos (deadline is the 20th of May) for this year's edition of the Prize.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Icon
News
26 April 2022
Oncode Investigators Bas van Steensel, Daniel Peeper and Alexander van Oudenaarden receive ERC Advanced Grant
Bas van Steensel and Daniel Peeper (both NKI) receive 2.5 million euro each. Van Steensel will use the grant to explore our messy genome while Peeper will focus on reinvigorating anticancer T cells.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Artwork 2
News
22 April 2022
Oncode finalizes Investigator Assessment in preparation for Phase 2
This year marks the final year of the first phase of Oncode Institute. Together with our funders, Oncode is working hard on putting together a new five-year plan to continue realizing our vision: outsmarting cancer, impacting lives. As a part of moving into Phase 2, Oncode Institute has been assessed by our International Advisory Board and International Review Committee. As part of the institute’s assessment, a large part of our 61 Oncode Investigator (OI) team has been evaluated.
PeterThijssen
Oncode Pact Persbericht beeld V2
News
14 April 2022
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs. With this investment, Oncode-PACT will develop valuable drug candidates faster and cheaper and thus bring them to patients sooner. This will improve the quality of life of cancer patients while strengthening the future economic earning capacity of the Netherlands.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Masterclass overview
News
7 April 2022
Finally live: looking back at the single-molecule imaging masterclass
On Thursday, 24 March 2022, at the NKI, we finally held a live masterclass again! This was the first masterclass on location since November 2019: an event organized by Oncode Investigators Marvin Tanenbaum (Hubrecht Institute) and Tineke Lenstra (NKI) with a guest lecture by Lukas Kapitein (Utrecht University).
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Oncode Icons Round reqruitment program
News
18 March 2022
Ruud Delwel’s experience with the NKI Robotics and Screening Center
Investing in (new) technologies and facilities - which are available to all Oncode researchers - is one of the ways in which Oncode contributes to breakthroughs in cancer research. The Oncode drug screening centres of expertise at the LUMC and the NKI are examples of such facilities. They provide Oncode researchers with advice and support to perform complex compound screens with the Drug Repurposing library. Oncode Investigator Ruud Delwel explains how he currently works with the drug screening center at the NKI.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Louis en marvin
News
17 March 2022
Oncode Investigators Louis Vermeulen and Marvin Tanenbaum receive ERC Consolidator Grant
Oncode Institute is proud to announce that Oncode Investigators Louis Vermeulen (Amsterdam AMC) and Marvin Tanenbaum (Hubrecht Institute) received the ERC Consolidator Grant. The ERC Consolidator Grants are awarded to outstanding researchers with at least seven and up to twelve years of experience after completing their PhD, and a scientific track record showing great promise.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
CRC organoid1 Snippert
News
10 March 2022
Shapeshifting cancer cells during liver metastasis formation
The groups of Oncode Investigators Hugo Snippert (UMC Utrecht), Jacco van Rheenen (Netherlands Cancer Institute) and Michiel Vermeulen (Radboud University), together with Onno Kranenburg (UMC Utrecht), Martijn Gloerich (UCM Utrecht) and Prisca Liberali (FMI, Basel) have characterized how a colorectal tumor cell evolves as soon as it metastasizes to the liver and delineated which events are critical to succeed. Their findings have been published in Cancer Research.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Illustration Agami Lab v1 11 01
News
9 March 2022
Tumor cell produces faulty proteins, even without DNA errors
Tumor cells produce proteins with tiny changes, even without prior changes in their DNA code: a phenomenon that has never been shown before and that is specifically seen in tumors. These proteins are different from their normal counterparts so that they can activate the human immune system. And that could provide us with new leads for new types of immunotherapy against cancer, in which “cold” tumors are made “hot.” This is the latest discovery by Oncode Investigator Reuven Agami’s research group, published in Nature.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.